Differences between high- and low-affinity complexes of enzymes and nonenzymes.
暂无分享,去创建一个
Heather A Carlson | Mark L. Benson | James B Dunbar | Mark L Benson | Paul D Kirchhoff | Richard D. Smith | H. Carlson | J. Dunbar | N. Khazanov | P. Kirchhoff | Richard D Smith | Nickolay A Khazanov
[1] Heather A Carlson,et al. Exploring protein-ligand recognition with Binding MOAD. , 2006, Journal of molecular graphics & modelling.
[2] Michael G. Lerner,et al. Binding MOAD (Mother Of All Databases) , 2005, Proteins.
[3] Thierry Langer,et al. Recent Advances in Docking and Scoring , 2005 .
[4] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[5] Christopher W Murray,et al. Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.
[6] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[7] R. Abagyan,et al. Comprehensive identification of "druggable" protein ligand binding sites. , 2004, Genome informatics. International Conference on Genome Informatics.
[8] P. Hajduk,et al. Predicting protein druggability. , 2005, Drug discovery today.
[9] Shaomeng Wang,et al. M-score: a knowledge-based potential scoring function accounting for protein atom mobility. , 2006, Journal of medicinal chemistry.
[10] I. Luque,et al. Structure-based prediction of binding affinities and molecular design of peptide ligands. , 1998, Methods in enzymology.
[11] K. Dill,et al. Partitioning of nonpolar solutes into bilayers and amorphous n-alkanes , 1990 .
[12] Dudley H. Williams,et al. Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes. , 2004, Angewandte Chemie.
[13] R. Nolen. 'Between a rock and a hard place'. , 2002, Journal of the American Veterinary Medical Association.
[14] Daniel R. Caffrey,et al. Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.
[15] Kerim Babaoglu,et al. Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.
[16] C. Chothia,et al. Hydrophobic bonding and accessible surface area in proteins , 1974, Nature.
[17] B Honig,et al. Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. , 1991, Science.
[18] Yuichi Sugiyama,et al. Druggability: selecting optimized drug candidates. , 2005, Drug discovery today.
[19] P. Hajduk,et al. Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.
[20] A. Bogan,et al. Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.
[21] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[22] I. Kuntz,et al. The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[23] Natasja Brooijmans,et al. Molecular recognition and docking algorithms. , 2003, Annual review of biophysics and biomolecular structure.
[24] Ryan T. Strachan,et al. Screening the receptorome: an efficient approach for drug discovery and target validation. , 2006, Drug discovery today.
[25] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[26] Ruth Nussinov,et al. Principles of docking: An overview of search algorithms and a guide to scoring functions , 2002, Proteins.
[27] Renxiao Wang,et al. The PDBbind database: methodologies and updates. , 2005, Journal of medicinal chemistry.
[28] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[29] P. Hajduk. Fragment-based drug design: how big is too big? , 2006, Journal of medicinal chemistry.
[30] W. Delano. Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.
[31] John C. Norvell,et al. Structural genomics programs at the US National Institute of General Medical Sciences , 2000, Nature Structural Biology.
[32] Hiroki Shirai,et al. Use of Amino Acid Composition to Predict Ligand-Binding Sites , 2007, J. Chem. Inf. Model..
[33] E. Jaeger,et al. Docking: successes and challenges. , 2005, Current pharmaceutical design.
[34] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[35] H. Kubinyi. Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.
[36] S. Lampel,et al. The druggable genome: an update. , 2005, Drug discovery today.
[37] Alan C. Cheng,et al. Structure-Based Identification of Small Molecule Binding Sites Using a Free Energy Model , 2006, J. Chem. Inf. Model..
[38] G. Crippen,et al. Prediction of Physicochemical Parameters by Atomic Contributions. , 1999 .
[39] K. Sharp,et al. Travel depth, a new shape descriptor for macromolecules: application to ligand binding. , 2006, Journal of molecular biology.
[40] L. Amzel,et al. Compensating Enthalpic and Entropic Changes Hinder Binding Affinity Optimization , 2007, Chemical biology & drug design.
[41] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[42] Christopher D. Thanos,et al. Hot-spot mimicry of a cytokine receptor by a small molecule , 2006, Proceedings of the National Academy of Sciences.